Ozempic blindness and lawsuits: what the evidence actually shows

What did @_smoothsayer actually say?

The creator opened with a joke about body dysmorphia and losing eyesight, then pivoted to a real-ish claim: Novo Nordisk is facing lawsuits alleging its GLP-1 products cause blindness. They also said Ozempic is "a diabetes medication first and foremost" and shared a personal story about a diabetic father-in-law who lost access during shortages. The eyesight claim was immediately called "a legend," then treated as credible seconds later. That whiplash framing is worth noting.

They didn't tell anyone to stop their medication or make dosage claims. But asking viewers if they're going to "keep using it now" after framing blindness as a live possibility is alarm without substance.

Does the science back this up?

Partially, and the nuance matters a lot here. A 2024 study published in JAMA Ophthalmology by Hathaway et al. found a statistically significant association between semaglutide use and non-arteritic anterior ischemic optic neuropathy (NAION), a type of vision loss caused by reduced blood flow to the optic nerve. The adjusted odds ratio was roughly 4.3 for semaglutide users with obesity. That sounds alarming, but context is everything.

NAION is rare. The absolute risk remains low, and the study was retrospective and observational, meaning it cannot establish causation. Researchers also noted that conditions like diabetes and cardiovascular disease, which many GLP-1 users have, are themselves independent risk factors for NAION. The FDA reviewed the data and said in mid-2024 that it was still evaluating the signal. No label change had been mandated as of early 2025. This is a legitimate scientific conversation, not a confirmed causal link.

What did they get wrong (or right)?

They got the core fact right: there is real scientific and legal attention on a possible link between semaglutide and a type of vision loss. The MDL 3094 reference in their caption is also real, though that litigation primarily centers on gastroparesis and failure-to-warn claims, not blindness specifically. Lumping those together without separation is sloppy.

What they got wrong is the framing. Saying users will "lose their eyesight" presents an observational signal as a near-certainty. The Hathaway et al. study found an association in a specific, relatively small patient group. Several ophthalmologists and endocrinologists have publicly cautioned against overinterpreting the findings. The creator also misspelled the drug name repeatedly, which is minor but does signal a surface-level engagement with the topic. Calling something a legend and then building an engagement hook around it isn't fact-checking, it's vibes-checking.

What should you actually know?

If you're taking semaglutide or any GLP-1 receptor agonist, the current evidence does not support stopping your medication over blindness fears. The FDA's position as of early 2025 is that it is monitoring the signal, not pulling the drug. The JAMA Ophthalmology study is worth knowing about, but it has real methodological limits. If you have pre-existing optic nerve conditions, cardiovascular disease, or diabetes-related eye complications, this is a specific conversation worth having with your prescribing doctor and potentially an ophthalmologist.

The shortage issue the creator mentioned is real and documented. Insulin and GLP-1 access disruptions during the Ozempic shortage affected people with type 2 diabetes who depended on these drugs medically, not just for weight loss. That part of the story deserved more airtime than the eyesight joke did.